A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects With Advanced Cancer (Schedule 1).
Phase of Trial: Phase I/II
Latest Information Update: 14 Oct 2015
At a glance
- Drugs BMS 753493 (Primary)
- Indications Advanced breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Renal cancer; Solid tumours
- Focus Adverse reactions; First in man
- 24 Mar 2012 Planned number of patients changed from 83 to 105 as reported by European Clinical Trials Database.
- 01 Jul 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 29 Jun 2010 Actual patient number (26) added as reported by ClinicalTrials.gov.